Comment: Avoiding detrimental effects of corticosteroids on JC virus T-cell responses-Primum non nocere

Igor J. Koralnik; David B. Clifford

doi:10.1212/WNL.0b013e3182768a21

Comment: Avoiding detrimental effects of corticosteroids on JC virus T-cell responses-Primum non nocere

Igor J. Koralnik
, David B. Clifford

Research output: Contribution to journal › Comment/debate

Original language	English
Pages (from-to)	2263
Number of pages	1
Journal	Neurology
Volume	79
Issue number	23
DOIs	https://doi.org/10.1212/WNL.0b013e3182768a21
State	Published - Dec 4 2012

Access to Document

10.1212/WNL.0b013e3182768a21

Cite this

@article{074207ceb1f845c7a3161756f60edab6,

title = "Comment: Avoiding detrimental effects of corticosteroids on JC virus T-cell responses-Primum non nocere",

author = "Koralnik, \{Igor J.\} and Clifford, \{David B.\}",

note = "Funding Information: I. Koralnik is funded by NIH grants R56 NS 041198, R01 NS 047029, R01 NS 074995, and K24 NS 060950 , and has received a research grant from Biogen Idec and the National Multiple Sclerosis Society. He served on scientific advisory boards for Hoffman La Roche, GlaxoSmithKline, and Merck Serono and received consulting fees from Bristol-Myers Squibb, Ono Pharmaceuticals, Merck Serono, Hoffman La Roche, GlaxoSmithKline, Perseid Therapeutics, Vertex Pharmaceutical, and Johnson \& Johnson. D. Clifford serves on Data Safety Boards for Biogen, GSK, Millennium, Genzyme, Genentech, and Pfizer. He has been a consultant to Amgen, Brinker, Biddle, Reath (PML Consortium), Genentech, Genzyme, Bristol-Myers Squibb, Millennium, Biogen Idec, and Pfizer. He has received research support from Biogen Idec, NeurogesX, Tibotec, and Pfizer. Go to Neurology.org for full disclosures. ",

year = "2012",

month = dec,

day = "4",

doi = "10.1212/WNL.0b013e3182768a21",

language = "English",

volume = "79",

pages = "2263",

journal = "Neurology",

issn = "0028-3878",

number = "23",

}

TY - JOUR

T1 - Comment

T2 - Avoiding detrimental effects of corticosteroids on JC virus T-cell responses-Primum non nocere

AU - Koralnik, Igor J.

AU - Clifford, David B.

N1 - Funding Information: I. Koralnik is funded by NIH grants R56 NS 041198, R01 NS 047029, R01 NS 074995, and K24 NS 060950 , and has received a research grant from Biogen Idec and the National Multiple Sclerosis Society. He served on scientific advisory boards for Hoffman La Roche, GlaxoSmithKline, and Merck Serono and received consulting fees from Bristol-Myers Squibb, Ono Pharmaceuticals, Merck Serono, Hoffman La Roche, GlaxoSmithKline, Perseid Therapeutics, Vertex Pharmaceutical, and Johnson & Johnson. D. Clifford serves on Data Safety Boards for Biogen, GSK, Millennium, Genzyme, Genentech, and Pfizer. He has been a consultant to Amgen, Brinker, Biddle, Reath (PML Consortium), Genentech, Genzyme, Bristol-Myers Squibb, Millennium, Biogen Idec, and Pfizer. He has received research support from Biogen Idec, NeurogesX, Tibotec, and Pfizer. Go to Neurology.org for full disclosures.

PY - 2012/12/4

Y1 - 2012/12/4

UR - https://www.scopus.com/pages/publications/84871271376

U2 - 10.1212/WNL.0b013e3182768a21

DO - 10.1212/WNL.0b013e3182768a21

M3 - Comment/debate

C2 - 23175725

AN - SCOPUS:84871271376

SN - 0028-3878

VL - 79

SP - 2263

JO - Neurology

JF - Neurology

IS - 23

ER -

Comment: Avoiding detrimental effects of corticosteroids on JC virus T-cell responses-Primum non nocere

Access to Document

Other files and links

Cite this